Accuracy of magnetic resonance imaging to identify pseudocapsule invasion in renal tumors.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 18 12 2018
accepted: 01 04 2019
pubmed: 27 4 2019
medline: 28 5 2020
entrez: 27 4 2019
Statut: ppublish

Résumé

To evaluate accuracy of MRI in detecting renal tumor pseudocapsule (PC) invasion and to propose a classification based on imaging of PC status in patients with renal cell carcinoma. From January 2017 to June 2018, 58 consecutive patients with localized renal cell carcinoma were prospectively enrolled. MRI was performed preoperatively and PC was classified, according to its features, as follows: MRI-Cap 0 (absence of PC), MRI-Cap 1 (presence of a clearly identifiable PC), MRI-Cap 2 (focally interrupted PC), and MRI-Cap 3 (clearly interrupted and infiltrated PC). A 3D image reconstruction showing MRI-Cap score was provided to both surgeon and pathologist to obtain complete preoperative evaluation and to compare imaging and pathology reports. All patients underwent laparoscopic partial nephrectomy. In surgical specimens, PC was classified according to the renal tumor capsule invasion scoring system (i-Cap). A concordance between MRI-Cap and i-Cap was found in 50/58 (86%) cases. ρ coefficient for each MRI-cap and iCap categories was: MRI-Cap 0: 0.89 (p < 0.0001), MRI-Cap1: 0.75 (p < 0.0001), MRI-Cap 2: 0.76 (p < 0.0001), and MRI-Cap3: 0.87 (p < 0.0001). Sensitivity, specificity, positive predictive value, negative predictive value, and AUC were: MRI-Cap 0: Se 97.87% Spec 83.3%, PPV 95.8%, NPV 90.9%, and AUC 90.9; MRI-Cap 1: Se 77% Spec 95.5%, PPV 83.3%, NPV 93.5%, and AUC 0.86; MRI-Cap 2- iCap 2: Se 88% Spec 90%, PPV 79%, NPV 95%, and AUC 0.89; MRI-Cap 3: Se 94% Spec 95%, PPV 88%, NPV 97%, and AUC 0.94. MRI-Cap classification is accurate in evaluating renal tumor PC features. PC features can provide an imaging-guided landmark to figure out where a minimal margin could be preferable during nephron-sparing surgery.

Identifiants

pubmed: 31025082
doi: 10.1007/s00345-019-02755-1
pii: 10.1007/s00345-019-02755-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

407-415

Références

Eur Urol. 2009 Jun;55(6):1410-8
pubmed: 18692300
Eur J Surg Oncol. 2014 Jun;40(6):762-8
pubmed: 24529794
J Urol. 2014 Jul;192(1):30-5
pubmed: 24373802
Radiographics. 2018 Nov-Dec;38(7):2021-2033
pubmed: 30339517
Clin Genitourin Cancer. 2016 Feb;14(1):69-75
pubmed: 26337654
J Urol. 1950 Aug;64(2):200-8
pubmed: 15429181
Eur Urol. 2015 Oct;68(4):705-12
pubmed: 26071789
J Comput Assist Tomogr. 1996 Nov-Dec;20(6):863-70
pubmed: 8933783
J Urol. 2017 Jan;197(1):23-30
pubmed: 27497792
Eur Urol. 2015 Dec;68(6):980-92
pubmed: 25911061
Minerva Urol Nefrol. 2017 Dec;69(6):523-538
pubmed: 28124871
J Urol. 1949 May;61(5):857-61
pubmed: 18127373
Arch Ital Urol Androl. 2009 Jun;81(2):96-9
pubmed: 19760864
Urol Oncol. 2018 Dec;36(12):527.e1-527.e11
pubmed: 30268711
J Urol. 2015 Sep;194(3):623-5
pubmed: 26073871
Eur Urol. 2012 Apr;61(4):757-63
pubmed: 22136987
Urology. 2014 Jun;83(6):1294-9
pubmed: 24713137
Radiology. 1985 Mar;154(3):709-15
pubmed: 3969475
Eur Urol. 1984;10(4):222-8
pubmed: 6479195
Urol Oncol. 2014 Jan;32(1):50.e15-22
pubmed: 24239462
Eur Urol. 2015 Oct;68(4):632-40
pubmed: 25922273
Virchows Arch. 2015 Sep;467(3):311-7
pubmed: 26089143
Urology. 2015 Nov;86(5):956-61
pubmed: 26126697
Eur Urol Focus. 2019 May;5(3):357-360
pubmed: 29174613
AJR Am J Roentgenol. 2005 Jan;184(1):113-20
pubmed: 15615960
Eur Urol. 2016 Aug;70(2):e47-50
pubmed: 26778463
Urol Oncol. 2017 Nov;35(11):661.e15-661.e21
pubmed: 28826700
J Urol. 2008 Jul;180(1):68-71
pubmed: 18485385
Clin Radiol. 2017 Nov;72(11):936-943
pubmed: 28673449
AJR Am J Roentgenol. 1996 May;166(5):1151-5
pubmed: 8615260
Eur Urol Focus. 2017 Oct;3(4-5):437-443
pubmed: 28753814
J Urol. 2017 Sep;198(3):520-529
pubmed: 28479239
J Urol. 2011 May;185(5):1604-10
pubmed: 21419454
Eur Urol. 2010 Mar;57(3):466-71
pubmed: 19359089

Auteurs

Rocco Papalia (R)

Department of Urology, Campus Bio-medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy. rocco.papalia@unicampus.it.

Valeria Panebianco (V)

Department of Radiological Sciences, Sapienza University of Rome, Rome, Italy.

Riccardo Mastroianni (R)

Department of Urology, Campus Bio-medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.

Maurizio Del Monte (M)

Department of Radiological Sciences, Sapienza University of Rome, Rome, Italy.

Emanuela Altobelli (E)

Department of Urology, Campus Bio-medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.

Eliodoro Faiella (E)

Department of Diagnostic and Interventional Radiology, Campus Bio-medico University of Rome, Rome, Italy.

Francesco Rosario Grasso (FR)

Department of Diagnostic and Interventional Radiology, Campus Bio-medico University of Rome, Rome, Italy.

Mariangela Bellangino (M)

Department of Urology, Ospedale Sant'Andrea, Sapienza University of Rome, Rome, Italy.

Giuseppe Simone (G)

Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy.

Massimo Ciccozzi (M)

Unit of Medical Statistics and Molecular Epidemiology, Campus Bio-medico University of Rome, Rome, Italy.

Silvia Angeletti (S)

Unit of Clinical Laboratory Science, Campus Bio-Medico University of Rome, Rome, Italy.

Giulia D'ovidio (G)

Department of Radiological Sciences, Sapienza University of Rome, Rome, Italy.

Carlo Catalano (C)

Department of Radiological Sciences, Sapienza University of Rome, Rome, Italy.

Michele Gallucci (M)

Department of Urology, Sapienza University of Rome, Rome, Italy.

Roberto Mario Scarpa (RM)

Department of Urology, Campus Bio-medico University of Rome, Via Alvaro del Portillo 200, 00128, Rome, Italy.

Giovanni Muto (G)

Department of Urology, Humanitas "Gardenigo" University, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH